-
Je něco špatně v tomto záznamu ?
Effect of immunosuppressive therapy in inflammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial
H. Poloczkova, J. Krejci, P. Hude, E. Ozabalova, J. Godava, T. Honek, V. Zampachova, I. Svobodova, T. Freiberger, L. Spinarova
Jazyk angličtina Země Slovensko
Typ dokumentu srovnávací studie, randomizované kontrolované studie, práce podpořená grantem
- MeSH
- azathioprin aplikace a dávkování MeSH
- dospělí MeSH
- imunosupresivní léčba * metody škodlivé účinky MeSH
- kardiomyopatie * farmakoterapie terapie MeSH
- kombinovaná farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- myokarditida farmakoterapie terapie MeSH
- prednison aplikace a dávkování MeSH
- prospektivní studie MeSH
- tepový objem účinky léků MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
- Geografické názvy
- Česká republika MeSH
INTRODUCTION: The indications for specific treatment in the cases of inflammatory cardiomyopathy are based on limited data from several small clinical trials. AIM: A comparison of the effect of two dose regimens of combined immunosuppressive therapy by adding them to conventional heart failure therapy and comparing them with conventional heart failure therapy alone in patients with inflammatory cardiomyopathy. METHODS AND STUDY POPULATION: We enrolled 20 patients; mean age 46.10±7.33 years, duration of symptoms <6 months, LVEF ≤40 %, NYHA class II–IV, with biopsy‐proven myocarditis. Patients were randomly separated into groups treated with immunosuppressive therapy in addition to conventional heart failure therapy or to a group treated with conventional heart failure therapy alone. Clinical and echocardiographic parameters were evaluated. RESULTS: The baseline values of LVEF in the group of immunosuppressive therapy (LVEF 22.3±4.7 %) were similar to those in the group treated with conventional heart failure therapy (LVEF 21.7±4.7 %; p=0.757). After twelve months there was no statistically significant difference in LVEF between the two studied groups (LVEF 33.7±9.5 % for the immunosuppressive therapy group and 41.3±13.0 % for the conventional therapy group; p=0.175). CONCLUSION: In our study population, we proved no positive effect of combined immunosuppressive therapy on the left ventricular function over 12 months. The main limitation of the study is the small number of enrolled patients (Tab. 4, Fig. 1, Ref. 35).
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22026095
- 003
- CZ-PrNML
- 005
- 20230110133906.0
- 007
- ta
- 008
- 221101s2022 xo d fs 000 0|eng||
- 009
- AR
- 024 0_
- $a 10.4149/BLL_2022_006 $2 doi
- 035 __
- $a (PubMed)34967656
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Poloczková, Hana $7 xx0121704 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
- 245 10
- $a Effect of immunosuppressive therapy in inflammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial / $c H. Poloczkova, J. Krejci, P. Hude, E. Ozabalova, J. Godava, T. Honek, V. Zampachova, I. Svobodova, T. Freiberger, L. Spinarova
- 504 __
- $a Literatura
- 520 9_
- $a INTRODUCTION: The indications for specific treatment in the cases of inflammatory cardiomyopathy are based on limited data from several small clinical trials. AIM: A comparison of the effect of two dose regimens of combined immunosuppressive therapy by adding them to conventional heart failure therapy and comparing them with conventional heart failure therapy alone in patients with inflammatory cardiomyopathy. METHODS AND STUDY POPULATION: We enrolled 20 patients; mean age 46.10±7.33 years, duration of symptoms <6 months, LVEF ≤40 %, NYHA class II–IV, with biopsy‐proven myocarditis. Patients were randomly separated into groups treated with immunosuppressive therapy in addition to conventional heart failure therapy or to a group treated with conventional heart failure therapy alone. Clinical and echocardiographic parameters were evaluated. RESULTS: The baseline values of LVEF in the group of immunosuppressive therapy (LVEF 22.3±4.7 %) were similar to those in the group treated with conventional heart failure therapy (LVEF 21.7±4.7 %; p=0.757). After twelve months there was no statistically significant difference in LVEF between the two studied groups (LVEF 33.7±9.5 % for the immunosuppressive therapy group and 41.3±13.0 % for the conventional therapy group; p=0.175). CONCLUSION: In our study population, we proved no positive effect of combined immunosuppressive therapy on the left ventricular function over 12 months. The main limitation of the study is the small number of enrolled patients (Tab. 4, Fig. 1, Ref. 35).
- 650 _7
- $a dospělí $7 D000328 $2 czmesh
- 650 _7
- $a lidé $7 D006801 $2 czmesh
- 650 _7
- $a lidé středního věku $7 D008875 $2 czmesh
- 650 _7
- $a výsledek terapie $7 D016896 $2 czmesh
- 650 17
- $a imunosupresivní léčba $x metody $x škodlivé účinky $7 D007165 $2 czmesh
- 650 17
- $a kardiomyopatie $x farmakoterapie $x terapie $7 D009202 $2 czmesh
- 650 _7
- $a myokarditida $x farmakoterapie $x terapie $7 D009205 $2 czmesh
- 650 _7
- $a prospektivní studie $7 D011446 $2 czmesh
- 650 _7
- $a kombinovaná farmakoterapie $7 D004359 $2 czmesh
- 650 _7
- $a prednison $x aplikace a dávkování $7 D011241 $2 czmesh
- 650 _7
- $a azathioprin $x aplikace a dávkování $7 D001379 $2 czmesh
- 650 _7
- $a tepový objem $x účinky léků $7 D013318 $2 czmesh
- 651 _7
- $a Česká republika $7 D018153 $2 czmesh
- 655 _7
- $a srovnávací studie $7 D003160 $2 czmesh
- 655 _7
- $a randomizované kontrolované studie $7 D016449 $2 czmesh
- 655 _7
- $a práce podpořená grantem $7 D013485 $2 czmesh
- 700 1_
- $a Krejčí, Jan $7 xx0204141 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Hude, Petr $7 stk2007393811 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Ozábalová, Eva $7 xx0107595 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Godava, Július $7 _AN028317 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Honek, Tomáš $7 xx0278697 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Žampachová, Víta $7 xx0088518 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Svobodová, Iva $7 xx0128976 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Freiberger, Tomáš, $d 1970- $7 xx0071641 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Špinarová, Lenka, $d 1961- $7 xx0061415 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
- 773 0_
- $t Bratislavské lekárske listy $x 0006-9248 $g Roč. 123, č. 1 (2022), s. 37-43 $w MED00000845
- 856 41
- $u http://www.elis.sk/download_file.php?product_id=7503&session_id=5hob67buame1h4jbqk1qin6737 $y plný text volně přístupný
- 910 __
- $a ABA008 $b online $c 1067 $y p $z 0
- 990 __
- $a 20221101161338 $b ABA008
- 991 __
- $a 20230110133902 $b ABA008
- 999 __
- $a ok $b bmc $g 1855389 $s 1177399
- BAS __
- $a 3
- BMC __
- $a 2022 $b 123 $c 1 $d 37-43 $i 0006-9248 $m Bratislavské lekárske listy $x MED00000845
- LZP __
- $c NLK189 $d 20221217 $a NLK 2022-22/kv